Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of celecoxib and docetaxel in treating patients who have non-small cell lung cancer.
Key facts
- Study ID
- NCT00030407
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 34
- Starts
- 2001-10-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2013-04-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.